Altratech has secured EUR 10.5 million (~USD 11.5 million) from the European Innovation Council’s (EIC) Accelerator Programme.
The company intends to channel these funds toward running clinical trials on HIV patients, scaling up manufacturing capabilities, and advancing product development efforts over the next three years. The company is also receiving ongoing support from Enterprise Ireland (EI) for developing its platform and conducting trials.
Altratech is a biotechnology company focused on developing innovative viral detection technologies, aiming to create a methodology or product that can detect any virus in a non-clinical setting without using an enzymatic step. Altratech's technology combines chemistry, biology, microfluidics, and silicon chip design to study viral detection outside of traditional settings.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.